[go: up one dir, main page]

MX2019001327A - Composiciones que comprenden sulfato de colesterol oxigenado y por lo menos uno de poli-alquilen-glicol, carboxi-metil-celulosa y polioxilglicerido. - Google Patents

Composiciones que comprenden sulfato de colesterol oxigenado y por lo menos uno de poli-alquilen-glicol, carboxi-metil-celulosa y polioxilglicerido.

Info

Publication number
MX2019001327A
MX2019001327A MX2019001327A MX2019001327A MX2019001327A MX 2019001327 A MX2019001327 A MX 2019001327A MX 2019001327 A MX2019001327 A MX 2019001327A MX 2019001327 A MX2019001327 A MX 2019001327A MX 2019001327 A MX2019001327 A MX 2019001327A
Authority
MX
Mexico
Prior art keywords
compositions
polyoxylglyceride
carboxymethyl cellulose
polyalkylene glycol
cholesterol sulfate
Prior art date
Application number
MX2019001327A
Other languages
English (en)
Other versions
MX391441B (es
Inventor
Lin Weiqi
Jean Kim Mee
R Miksztal Andrew
Wu Hongwei
L Lee Min
Chao Wendy
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp filed Critical Durect Corp
Publication of MX2019001327A publication Critical patent/MX2019001327A/es
Publication of MX391441B publication Critical patent/MX391441B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Se proporcionan composiciones que comprenden sulfatos de colesterol oxigenados (OCS). El OCS es, por ejemplo, 3-sulfato de 5-colesteno-3, 25-diol (25HC3S) o disulfato de 5-colesteno-3, 25-diol (25HCDS). Las composiciones se pueden utilizar para la prevención y/o el tratamiento de una variedad de enfermedades y afecciones, con la inclusión de la falla de los órganos (por ejemplo, una falla aguda del hígado debida al acetaminofeno), colesterol alto/lípidos altos, y diferentes enfermedades y afecciones inflamatorias.
MX2019001327A 2016-08-02 2017-08-01 Composiciones que comprenden sulfato de colesterol oxigenado y por lo menos uno de poli-alquilen-glicol, carboxi-metil-celulosa y polioxilglicerido. MX391441B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662370200P 2016-08-02 2016-08-02
US201762470834P 2017-03-13 2017-03-13
PCT/US2017/044934 WO2018026837A1 (en) 2016-08-02 2017-08-01 Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride

Publications (2)

Publication Number Publication Date
MX2019001327A true MX2019001327A (es) 2019-07-08
MX391441B MX391441B (es) 2025-03-21

Family

ID=61074228

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001327A MX391441B (es) 2016-08-02 2017-08-01 Composiciones que comprenden sulfato de colesterol oxigenado y por lo menos uno de poli-alquilen-glicol, carboxi-metil-celulosa y polioxilglicerido.

Country Status (12)

Country Link
US (2) US20200222430A1 (es)
EP (1) EP3493810A4 (es)
JP (2) JP7048576B2 (es)
KR (1) KR102462275B1 (es)
CN (1) CN109922811B (es)
AU (1) AU2017305305A1 (es)
BR (1) BR112019001225A2 (es)
CA (1) CA3031215A1 (es)
IL (1) IL264391A (es)
MX (1) MX391441B (es)
TW (1) TW201818946A (es)
WO (1) WO2018026837A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
MX2021011641A (es) 2013-12-24 2023-03-10 Durect Corp Usos de sulfatos de colesterol oxigenados (soc).
HUE059768T2 (hu) 2016-08-02 2022-12-28 Univ Virginia Commonwealth 5-kolesztén-3,25-diol, 3-szulfátot (25HC3S) vagy annak gyógyszerészetileg elfogadható sóját és legalább egy ciklikus oligoszacharidot tartalmazó készítmények
US20220276139A1 (en) * 2019-07-08 2022-09-01 The University Of Hong Kong Compositions and methods for clearing tissue
US20220378802A1 (en) * 2019-09-30 2022-12-01 Durect Corporation Treatment of alcoholic hepatitis
KR20220119459A (ko) * 2019-12-27 2022-08-29 듀렉트 코퍼레이션 결정질 및 액상 결정질 25-히드록시-콜레스트-5-엔-3-술페이트 소듐 및 이의 제조 방법
AU2021221109A1 (en) * 2020-02-11 2022-08-25 Durect Corporation Treatment of infectious diseases
CN115551480B (zh) * 2020-04-15 2025-11-18 格吕伦塔尔有限公司 树脂毒素组合物
JP2023527153A (ja) * 2020-05-22 2023-06-27 デュレクト コーポレーション 非アルコール性脂肪性肝炎（ｎａｓｈ）の処置
TW202210082A (zh) * 2020-05-22 2022-03-16 美商杜瑞克公司 非酒精性脂肪肝炎（ｎａｓｈ）之治療
EP4359420A4 (en) * 2021-06-25 2025-07-16 Durect Corp 25-HYDROXY-CHOLEST-5-EN-3-SULFATE CHOLINE, PROCESSES FOR THEIR PREPARATION, AND THEIR USES
CN114306350B (zh) * 2022-01-13 2023-01-24 四川大学华西医院 胆固醇硫酸盐在制备预防脓毒症的药物中的用途
CN114646702B (zh) * 2022-03-03 2023-01-06 四川大学华西医院 胆固醇硫酸酯检测试剂在制备脓毒症辅助诊断、治疗效果监测和预后评估试剂盒中的用途
JP2026501266A (ja) * 2022-12-23 2026-01-14 デュレクト コーポレーション ２５－ヒドロキシ－コレスタ－５－エン－３－スルファートの結晶性塩を含む塩、及びその調製方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
IS6633A (is) 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US20090149434A1 (en) 2005-09-29 2009-06-11 Joseph Podolski Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
US8044243B2 (en) 2006-02-13 2011-10-25 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US8003795B2 (en) 2007-06-22 2011-08-23 Cvi Pharmaceuticals Limited Compounds and compositions for reducing lipid levels
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
CN106083976B (zh) 2012-04-12 2018-02-09 弗吉尼亚联邦大学 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5‑胆甾烯‑3β,25‑二醇二硫酸酯(25HCDS)
EP2842547A1 (en) * 2013-08-27 2015-03-04 Freund Pharmatec Ltd. Improved fenofibrate compositions
MX2021011641A (es) * 2013-12-24 2023-03-10 Durect Corp Usos de sulfatos de colesterol oxigenados (soc).
WO2016005994A2 (en) 2014-07-06 2016-01-14 Gattefosse India Pvt. Ltd. Pharmaceutical composition comprising solid dispersion of bcs class ii drugs with gelucires
CN107106576A (zh) 2014-10-10 2017-08-29 弗吉尼亚联邦大学 用于因减弱的瘦蛋白活性和脂质贮积障碍中的至少一种导致的障碍的疗法的氧化胆固醇硫酸酯类

Also Published As

Publication number Publication date
EP3493810A4 (en) 2020-04-08
KR102462275B1 (ko) 2022-11-01
AU2017305305A1 (en) 2019-02-21
JP2019526542A (ja) 2019-09-19
KR20190032529A (ko) 2019-03-27
TW201818946A (zh) 2018-06-01
IL264391A (en) 2019-02-28
CN109922811A (zh) 2019-06-21
EP3493810A1 (en) 2019-06-12
CA3031215A1 (en) 2018-02-08
WO2018026837A1 (en) 2018-02-08
MX391441B (es) 2025-03-21
BR112019001225A2 (pt) 2019-04-30
US20200222430A1 (en) 2020-07-16
US20220175798A1 (en) 2022-06-09
CN109922811B (zh) 2023-09-19
JP2022084831A (ja) 2022-06-07
JP7048576B2 (ja) 2022-04-05

Similar Documents

Publication Publication Date Title
MX2019001327A (es) Composiciones que comprenden sulfato de colesterol oxigenado y por lo menos uno de poli-alquilen-glicol, carboxi-metil-celulosa y polioxilglicerido.
MX2022012536A (es) Composiciones que comprenden polisacaridos sulfatados.
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CO2018003678A2 (es) Composiciones y métodos para inhibir la expresión génica de lpa
MX2024012899A (es) Metodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatias
MX2022013429A (es) Composiciones que comprenden 3-sulfato de 5-colesteno-3, 25-diol (25hc3s), o una sal farmaceuticamente aceptable del mismo, y por lo menos un oligosacarido ciclico.
CO2019002371A2 (es) Adenovirus armado con captador biespecífico de linfocitos t (bite)
CL2018003429A1 (es) Compuestos novedosos como inhibidores de la autotaxina y composiciones farmacéuticas que los comprenden.
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
MX2019003397A (es) Metodos para tratar trastornos mitocondriales y metabolicos.
MX2017015990A (es) Composiciones topicas que comprenden un corticosteroide y un retinoide para tratar psoriasis.
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
CL2020001226A1 (es) Proceso para preparar tapinarof.
BR112017012377A2 (pt) conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
AR113134A1 (es) Arni variante
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
BR112017021559A2 (pt) composições e métodos para tratamento sinérgico do glicocálice
MX2023012640A (es) Uso de profarmacos de riluzol para tratar ataxias.
EP3583066A4 (en) COMPOSITE NANOPARTICLE COMPOSITIONS AND ARRANGEMENTS
CR20170498A (es) 2-tiopirimidinonas
MX2017006747A (es) Amidas de acidos grasos para la prevencion y/o tratamiento de la esteatohepatitis.
BR112019002213A2 (pt) composições e o uso das mesmas para tratar ou prevenir rosácea
AR101097A1 (es) Método para el tratamiento de superficies de alimentos con ésteres de aminoácidos
AR101786A1 (es) Composiciones parenterales y usos de las mismas